JMP Securities Maintains Market Outperform on Zimmer Biomet Holdings, Lowers Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly has maintained a Market Outperform rating on Zimmer Biomet Holdings (NYSE:ZBH) but has reduced the price target from $160 to $140.

November 13, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JMP Securities reaffirmed a Market Outperform rating on Zimmer Biomet Holdings, but lowered the price target from $160 to $140.
While the reaffirmation of the Market Outperform rating suggests continued confidence in Zimmer Biomet's prospects, the reduction in the price target could signal a tempered expectation for the stock's performance. This might lead to a neutral short-term impact as the positive rating is counterbalanced by a lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100